CN1439378A - Preparation for wound hemostatics and suture zipper - Google Patents
Preparation for wound hemostatics and suture zipper Download PDFInfo
- Publication number
- CN1439378A CN1439378A CN 02103059 CN02103059A CN1439378A CN 1439378 A CN1439378 A CN 1439378A CN 02103059 CN02103059 CN 02103059 CN 02103059 A CN02103059 A CN 02103059A CN 1439378 A CN1439378 A CN 1439378A
- Authority
- CN
- China
- Prior art keywords
- wound
- slide fastener
- preparation
- closure
- healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 23
- 229940030225 antihemorrhagics Drugs 0.000 title claims description 14
- 239000002874 hemostatic agent Substances 0.000 title claims description 13
- 230000002439 hemostatic effect Effects 0.000 title claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 59
- 206010052428 Wound Diseases 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001661 Chitosan Polymers 0.000 claims abstract description 17
- 230000029663 wound healing Effects 0.000 claims abstract description 12
- 239000004310 lactic acid Substances 0.000 claims abstract description 11
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 11
- 230000035876 healing Effects 0.000 claims abstract description 10
- 231100000241 scar Toxicity 0.000 claims abstract description 5
- 239000000835 fiber Substances 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 230000023597 hemostasis Effects 0.000 claims description 8
- 239000003292 glue Substances 0.000 claims description 6
- 208000032843 Hemorrhage Diseases 0.000 claims description 4
- 229920000297 Rayon Polymers 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229920000018 Callose Polymers 0.000 claims description 2
- 229920000715 Mucilage Polymers 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000036074 healthy skin Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000012780 transparent material Substances 0.000 claims 1
- 210000000589 cicatrix Anatomy 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000012567 medical material Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229920001864 tannin Polymers 0.000 description 6
- 235000018553 tannin Nutrition 0.000 description 6
- 239000001648 tannin Substances 0.000 description 6
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010053692 Wound complication Diseases 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229920002824 gallotannin Polymers 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229910001341 Crude steel Inorganic materials 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010073520 Skin scar contracture Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- -1 bandage Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
A wound-healing anastaltic medicine is prepared from chitosan, lactic acid and alcohol. Its advantages are high staltic speed, speedy healing, relievable pain and no residual scar. A zipper of wound is inclosed, which can be used in conjunction with said wound-healing anastaltic medicine.
Description
Present known wound hemostatic agent has; Chinese drugs agentia, chemical antiphlogistic medicament, bandage, products such as wound healing protecting film, but all unsatisfactory.Though the medicine that has hemostasis is fast,, can stay cicatrix behind the wound healing; The medicine wound healing that has is slow and have pair to do.Cicatrix, be that bodily tissue is repaired the product in the wound process, because a series of dysfunctions such as adhesion of tendon, joint stiffness, skin scar contracture can take place in the growth of cicatrix.Any damage all may form cicatrix, and this is a kind of biological respinse of tissue.The cicatrix that wound is heavy more, tissue defect is many more, form is just many.How reducing wound and form cicatrix, is the problem that people pay attention to.According to relevant bibliographical information; Britain one tame biotech firm develops a kind of wound healing that can promote recently and does not forge the medicament of cicatrix again.Developing at present the device that a kind of appearance looks like this medicament of injection of a crude steel pen, " pen " of this healing skin trauma will be provided to the nursing staff or the soldier of army of hospital, hemorrhage with prevention human body sudden trauma, avoid the harm that too much life is brought because of bleeding.
Hemostatics of the present invention, be to make with the high-molecular biologic polymer, have hemostasis fast, alleviate wound pain, accelerating wound effect, and have the antibiotic and sterilizing ability, promote behind granulation energy for growth, skin regeneration ability, the wound healing effect such as preventing from scar.
Feature of the present invention is to adopt biopolymer polymer chitosan (chemical name is (1.4)-2-amino-2-deoxidation-callose) for main material, is that auxiliary material are prepared from lactic acid, ethanol.Chitosan is the known unique positively charged cation edibility animal fiber of present occurring in nature.Its chemical molecular structure is:
Study document by retrieval both at home and abroad and show that the molecular structure of chitosan self and biological activity have good affinity to human body cell, can promote cell activation, and can be absorbed by the body well, human body does not produce rejection to it.Chitosan is the natural sex cellulose, and the same with white sugar (lethal dose of chitosan is per kilogram of body weight 16 grams through experimentation, chitosan avirulence, its safety; And the lethal dose of white sugar is per kilogram of body weight 18 grams).The present invention has just utilized the chitosan These characteristics.
After people's skin was punctured scuffing, because it is destroyed to make skin have collagen fiber of intensity, therefore, wound healing promptly was the repair process of collagen fiber growth to skin.New collagen fiber are constantly growth on old collagen fiber, though repaired wound, but still can stay cicatrix.Feature of the present invention just is, with the lactic biological fiber polymer of this method preparation, smeared or after aerosol is ejected on the wound, and bactericidal haemostatic rapidly, and form fibrous wire mesh membrane at skin surface.Collagen fiber are constantly growth on wire mesh membrane, rather than grows on old collagen fiber.Collagen fiber are grown on wire mesh membrane, form fine and close skin rapidly rather than are formed fragile scar tissue, so it has not only promoted the healing of wound but also do not stay cicatrix.According to literature search, domestic existing also develop have that Patent right chitosan extension product " can absorb the wound suture line ", " styptic cotton ", " artificial skin " etc., but, relevant as the present invention's hemostasis rapidly, bactericidal antiphlogistic, not only promoted the healing of wound but also do not stay the content of the novel hemostatics of cicatrix, yet there are no report.
Feature of the present invention (1) has been to utilize chitosan that human body cell is had good affinity, can promote cell activation, be absorbed by the body well, and human body does not produce the characteristics of rejection.At this we to advise using deacetylation be chitosan product more than 85%.Chitosan can be dissolved in the multiple acidic liquid, and can be used in of the present invention can be acetic acid, lactic acid.Through experiment, we think that the lactic acid solution of, disinfection anticorrosion to have is for well.The acid fiber polymer that lactic acid and chitosan generate can promote bodily tissue regeneration, the positive reparation of carrying out wound and hemostasis, bactericidal antiphlogistic effect.Manufacture method is; In 95 parts of distilled water, add 2.5 parts of lactic acid, in slowly stirring, adding 2.5 parts of chitosans again, treat chitosan all after the dissolving, leave standstill to the liquid bubble and disperse and become as clear as crystal liquid, form the lactic biological fiber polymer.The configuration proportion scope is:
Distilled water 90--96%
Lactic acid 2--4%
Chitosan 2--6%
Feature of the present invention (2) is to add ethanol in the lactic biological fiber polymer.Method is that the lactic biological fiber polymer as method preparation as described in the right (1) is adding ethanol again in slowly stirring.That ethanol plays a part in this medicament is anticorrosion, disinfection and promotion fiber polymerization film formation.Solution pH value scope after the configuration should be between 4.6--5.8.Because of the lactic biological fiber polymer when the acidity, its contained amino is the cation shape, antimicrbial power is strong; Antimicrbial power lowers when neutral and alkaline.In the hemostatics of the present invention, the ethanol allocation ratio can not be greater than 50%; If ratio is excessive, then bigger to skin irritation, so configuration proportion should be less than 50%.The allocation ratio scope is as follows:
Acid fiber polymer 35--65%
Ethanol 15--48%
The proposed arrangement ratio is acid fiber polymer 58% ethanol 42%
As medicament of the present invention being used in large-area wound face patient treatment, the proposed arrangement ratio is acid fiber polymer 68% ethanol 10% (adopting the aerosol injection method).
As medicament of the present invention being used in the patients with bedsore treatment, the proposed arrangement ratio is acid fiber polymer 52% ethanol 48% (concentration of alcohol is 12%).
Feature of the present invention (3) is in the acid fiber polymer of being prepared as right (1), adds the Chinese crude drug Rhizoma Polygoni Cuspidati and is used for burn.
Through laboratory observation, carry out the test of white mice hepatotoxicity with Rhizoma Polygoni Cuspidati, basis, Pericarpium Granati, Fructus Chebulae, Radix Sanguisorbae, Cortex Ziziphi spinosae Radicis tannin, with 0.5% Gallotannin concentration is standard, is mixed with various corresponding concentration respectively, makes subcutaneous injection with the dosage of 0.2 milliliter of per 10 gram body weight.Continuous two days once a day.Observe serum glutamic pyruvic transminase and change and liver Histological change, found that the variation of the two is substantially parallel.The toxicity of Rhizoma Polygoni Cuspidati, this tannin of that belongs to condensed type is low than Pericarpium Granati, Fructus Chebulae, Radix Sanguisorbae, Cortex Ziziphi spinosae Radicis, the Gallotannin of hydrolysis-type.White mice liver after the injection Rhizoma Polygoni Cuspidati tannin is checked Non Apparent Abnormality.This shows that the Rhizoma Polygoni Cuspidati tannin is to seldom toxigenicity reaction of liver.If use same dosage, Xiao Jiliang Galla Chinensis (being contained on the pharmacopeia " medicinal tannin ") tannin compares even, and then latter's liver occurs obviously downright bad.Its ingredient of burn medicament of the present invention is:
Rhizoma Polygoni Cuspidati fluid 15% (by contained tincture preparation method preparation on the pharmacopeia)
Lactic acid polymer 65%
Burn medicament of the present invention also can be used for large-area burn treating.This medicament preferably adopts ejection medium, and burns 50% sprays medical material 50%.
The hemostatics that the method for being prepared as right (1) (2) prepares is used in wound hemostasis and healing.Needing the wound of operation needle, feature of the present invention for surgery is to sew up with slide fastener, replaces the part operation needle.Method is hemostatics to be injected the wound suture slide fastener of this method preparation, and wound just heals in slide fastener, and can not stay cicatrix after healing (see description pay figure).
Its feature of wound suture slide fastener of the present invention (4) is the slide fastener chain of two I shapes, with kerve mode closure of wound.Joint strip is avoided contacting with wound from the width that wound leaves the 4-6 millimeter.The chain bottom scribbles viscose glue, with release paper protects joint strip mucilage glue surface.During use release paper is torn.Stick on the skin of 2 millimeters of wounds.
As the zip strip of right (4) preparation, its feature (5) is can be with the lid card of slide fastener closure.The lid card inserts in the groove of two slide fasteners, upwards draws in to make wound closure.After the slide fastener closure, the space of 4-6 millimeter should be arranged at the bottom.Expose wound and be beneficial to treatment.
As having aperture on the slide fastener closing lid card of right (5) preparation, feature of the present invention (6) the closing lid card, it is ventilative and inject the wound healing medicament to be convenient to wound.
As the wound closure slide fastener of right (3) (4) preparation, feature of the present invention (7) slide fastener back is prepared into closed, and chain is made the embossed card shape respectively with lid card front.After the slide fastener closure, with the embossed card closure, slide fastener is fixed can not move forward and backward.
Feature of the present invention (8) is that closing lid card the place ahead connects drawstring, the bottom scribbles viscose glue, after the slide fastener closure drawstring is sticked at fixed cap card on the healthy skin.
As the wound closure slide fastener of right (3) (4) preparation, feature of the present invention (9) also can be made the wound closure slide fastener H type catching groove.
The using method of wound suture slide fastener is: at first that wound clean is clean; the closed OK a karaoke club of suture zipper is opened, torn slide fastener bottom protection gummed paper, suture zipper is sticked on the skin of 2 millimeters of wounds; then the closed card of slide fastener is inserted in the slide fastener catching groove of both sides, upwards draw in making wound closure.After checking wound closure, the protection gummed paper of drawstring is torn, sticks on the skin.After checking that whole slide fastener and skin adhesive are firm, on the passage that blocks from the slide fastener closure, the wound, allow wound in slide fastener, heal again with wound hemostasia and healing agent injection suture zipper.
The hemostatics of the present invention's preparation, burn medicament are the toughness colloid.This medicament preferably adopts ejection medium, the injection medicine of this liquefaction preferably room temperature and atmosphere depressed state be gas promptly: boiling point under atmospheric pressure will be lower than 20 ℃, the injection medicine of this liquefaction should not have toxicity.Picture sprays medical material dichlorodifluoromethane (injection medical material 12 ') 1,2-dichlorotetra-fluoroethane (injection medical material 114 ') fluoro trichloromethane (injection medical material 11 '), and above-mentioned injection medicine also can be by different proportion mixing use.Be to be suitable for safe.Wound hemostasia and healing aerosol allocation ratio is: lactic acid polymer 50% sprays medical material 50%.Burns 50% sprays medical material 50%.
The present invention is the preparation method that is to provide a kind of new bio medicine, hemostatics, burn medicament and wound suture slide fastener.Hemostatics has hemostasis fast, alleviates wound pain, and effects such as accelerating wound, and have the antibiotic and sterilizing ability promote the granulation energy for growth, skin regeneration ability, effect such as preventing from scar behind the wound healing.It is hemorrhage that this medicine is used in various exogenous injury of human body, surgical operation hemostasis and healing treatment, patients with bedsore treatment, diseases such as burn.Product no side effects of the present invention.The wound suture slide fastener is used in the part wound suture, and its method is simple, can reduce the misery of patient's suture needle, not easy infection, the variation that can observe directly wound, economically feasible.
Claims (9)
1 one kinds of treatment exogenous injury of human body are hemorrhage, preventing from scar medicaments preparation method behind the wound healing.Feature of the present invention is to be dissolved in the lactic acid solution with biopolymer polymer chitosan (chemical name is (1.4)-2-amino-2-deoxidation-callose), forms lactic acid macromolecular fibre polymer.
2. one kind according to the desired preparation method of right (1), and eigen is to add ethanol in the high molecular lactic copolymer of preparation, and adjusting pH value is that 4.6-5.8 is used in the treatment of all kinds wound hemostasia and healing, patients with bedsore treatment.
3. one kind according to the desired preparation method of right (1), and eigen is to add the Chinese crude drug Rhizoma Polygoni Cuspidati to be used for burn in the high molecular lactic copolymer of preparation.
The hemostatics produced of the method for being prepared as right (1) and (2), be used in the wound hemostasis and healing treatment, the wound that needs operation needle for surgery, the present invention uses the slide fastener closure of wound, inject hemostatics from the slide fastener hole to wound again, wound is healed in slide fastener, replace the part operation needle.It is characterized in that the zip strip of two I shapes, with kerve mode closure of wound.Chain and wound leave the space of 4-6 millimeter. and the chain bottom scribbles viscose glue, with release paper protects chain mucilage glue surface.
5. zip strip according to right (4) preparation, eigen is can be with the lid card of slide fastener closure.Gai Kake inserts in the groove of two slide fasteners, upwards draws in to make wound closure.Closed back, lid card from wound have the 3-4 millimeter height, avoid contacting with wound.The closing lid card uses transparent material to make, and can observe directly the variation of wound.
6. the slide fastener closing lid card according to right (5) preparation has aperture on the lid card, is convenient to ventilative and injection wound healing medicament.
7. the wound closure slide fastener according to right (4) (5) preparation covers the card back and is prepared into closed, and chain is made the embossed card shape respectively with lid card front.After the slide fastener closure, with the embossed card closure, slide fastener is fixed can not move forward and backward.
8. closing lid card according to right (5) preparation, the place ahead connects drawstring, the bottom scribbles viscose glue, after the slide fastener closure zipper strip is sticked on the healthy skin.
9. the wound closure slide fastener according to right such as right (4) (5) preparation also can be made into H type catching groove.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02103059 CN1439378A (en) | 2002-02-20 | 2002-02-20 | Preparation for wound hemostatics and suture zipper |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02103059 CN1439378A (en) | 2002-02-20 | 2002-02-20 | Preparation for wound hemostatics and suture zipper |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1439378A true CN1439378A (en) | 2003-09-03 |
Family
ID=27792991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02103059 Pending CN1439378A (en) | 2002-02-20 | 2002-02-20 | Preparation for wound hemostatics and suture zipper |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1439378A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716516A (en) * | 2012-05-11 | 2012-10-10 | 天津大学 | Polydatin modified collagen scaffold, and preparation method and application thereof |
| CN105873525A (en) * | 2014-01-05 | 2016-08-17 | 奇普林医药公司 | Instrumented wound closure device |
| CN107213193A (en) * | 2017-07-17 | 2017-09-29 | 河西学院 | Application of the wild Sophora alopecuroide in terms of stopping blooding and promoting wound healing |
| CN107569263A (en) * | 2017-09-06 | 2018-01-12 | 河南亚都实业有限公司 | Medical sutures device |
-
2002
- 2002-02-20 CN CN 02103059 patent/CN1439378A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716516A (en) * | 2012-05-11 | 2012-10-10 | 天津大学 | Polydatin modified collagen scaffold, and preparation method and application thereof |
| CN102716516B (en) * | 2012-05-11 | 2014-02-26 | 天津大学 | Collagen scaffold modified by polydatin and its preparation method and application |
| CN105873525A (en) * | 2014-01-05 | 2016-08-17 | 奇普林医药公司 | Instrumented wound closure device |
| CN107213193A (en) * | 2017-07-17 | 2017-09-29 | 河西学院 | Application of the wild Sophora alopecuroide in terms of stopping blooding and promoting wound healing |
| CN107569263A (en) * | 2017-09-06 | 2018-01-12 | 河南亚都实业有限公司 | Medical sutures device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mirbagheri et al. | Chitosan-based electrospun nanofibers for diabetic foot ulcer management; recent advances | |
| CN103083713B (en) | A kind of aseptic polymerization wound-surface cover dressing | |
| CN106822988B (en) | Alginate fiber functional dressing and application thereof, and alginate fiber functional dressing patch | |
| UA123822C2 (en) | New standardizations & medical devices for the preparation of platelet rich plasma (prp) or bone marrow centrate (bmc) alone or in combination with hyaluronic acid | |
| WO1993012801A1 (en) | Pharmaceutical composition for the treatment of wounds, scars and keloids | |
| CN101485897A (en) | Biocompatible, hemostatic, anti-adhesion, healing-promoting and surgically-occlusive modified starch material | |
| DE60115433T2 (en) | METHOD FOR THE TREATMENT OF CHRONIC DISEASES | |
| CN107184961A (en) | A kind of competent cell renovation agent and preparation method thereof | |
| CN110507845A (en) | Biological composite ventilating dressing and preparation method thereof | |
| Gokarneshan | Application of natural polymers and herbal extracts in wound management | |
| CN101926872A (en) | Chinese medicinal detoxifying myo-regeneration paste for treating diabetic foot ulcer and preparation method thereof | |
| CN102274493B (en) | Bleeding-stopping, inflammation-diminishing and pain-relieving nano emulsion for use in minimally invasive beauty treatment therapy and preparation method thereof | |
| CN1298972A (en) | Hydro-entangled non-woven chitin fibre cloth and its production method | |
| CN108686103B (en) | Hemostatic traditional Chinese medicine composition and multifunctional emergency hemostatic composite material | |
| CN1439378A (en) | Preparation for wound hemostatics and suture zipper | |
| CN106975098A (en) | A kind of complex polysaccharide hemostatic composition and preparation method and application | |
| CN109700998A (en) | A kind of compound skin injury regeneration renovation agent and preparation method thereof | |
| Khorasani et al. | The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
| WO2017030388A1 (en) | Composition for treating skin wounds | |
| CN1246021C (en) | Non-scar plaster for treating trauma and its preparing process and usage | |
| CN109157672A (en) | A kind of preparation method of fibroin-small peptide blood coagulation microballoon | |
| CN1686158A (en) | Adhesive bandage containing hyaluronic acid biological composition | |
| Elfatah et al. | Evaluation of nanofat injection in postburn and post-traumatic facial scars. | |
| CN114984294A (en) | Dressing and preparation method thereof | |
| CN113521523A (en) | Microneedle drug delivery system for treating wound surface and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |